Erin Johanek, PharmD, RPh

Why cost and treatment length are some of the biggest concerns for drug manufacturers.

The current and future treatments for the $10 billion condition.

New cancer drugs continue to offer patients hope. Here are eight of them.

This year has been another year full of oncology approvals, proving that the oncology pipeline is robust with first-of-the kind molecules, competitor products for existing agents, and biosimilars.

Not all therapies work the same in every patient, but that’s not the biggest challenge in treating mental health. This is.

Vaccines are an important part of creating “herd immunity” to keep infectious diseases in check. Here are three vaccine developments that have far reaching implications for public health.

Oncology experts shed light on progress of genetic testing and targeted therapies in lung cancer.

There is no cure for HIV, but with proper medical treatment, the disease can be controlled.

Treatment failures can result in a spectrum of problems for patients with hemophilia. Here’s some guidance on choosing the right therapy.

More targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.

While targeted cancer therapies make up a big part of the pipeline, there are three areas that oncology experts want you to keep on your radar.

More support for clinical trials and a wider lens for rare diseases in children sets the category on fire.

As more specialty drugs are approved, cost control strategies are key.

The next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.

Novo Nordisk’s DEVOTE study reveals interesting findings.

FDA approves new diagnostic test for non-small cell lung cancer.

FDA approved the use of a new fluoroquinolone antibiotic to treat ABSSSI.

Cost burden prompts payers to consider appropriate utilization

Potential public health consquences prompts FDA to request removal of opioid pain medication.

Adamis’ epinephrine injection promises to be a lower-cost alterative to EpiPen.

The first generic Truvada for treating and preventing HIV will be available, but when?

FDA approves Isentress at a higher dose for HIV-1 infected patients.

A new trial for AstraZeneca’s benralizumab shows promising results for severe asthma patients.

FDA has approved the first generic versions of Strattera (atomoxetine) for the treatment of attention deficit/hyperactivity disorder.

Although drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.

Lilly's galcanezumab proves successful in three phase 3 migraine studies. Here are the findings.

AstraZeneca voluntarily recalls professional samples of its antiplatelet agent. Here's what to do.

FDA approves ribociclib plus letrozole to treat a subset of advanced breast cancer patients.

The 13th edition EMD Serono Specialty Digest outlines top specialty drug management issues health plans face.

A new study led by The University of California researchers and published in JAMA reveals surprising findings.